LY 007
Alternative Names: CD 20 CAR-T cell therapy - Shanghai Longyao Biotechnology; LY-007Latest Information Update: 26 Feb 2025
At a glance
- Originator Shanghai Longyao Biotechnology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 26 Feb 2025 LY 007 is still in phase I clinical trials for Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT06279611)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 07 Dec 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)